Navigation Links
Volcano Reports Record Third Quarter Revenues
Date:11/8/2007

9 1,516

Interest expense (144) - (144)

Interest and other income, net 192 - 192

Income before provision for income

taxes 755 809 1,564

Provision for income taxes 254 - 254

Net income $501 $809 $1,310

Net income per share - basic $0.02 $0.02 $0.04

Net income per share - diluted $0.01 $0.02 $0.04

Weighted-average shares

outstanding - basic 32,976 32,976

Weighted-average shares

outstanding - diluted 36,900 36,900

VOLCANO CORPORATION

RECONCILIATION OF GAAP AND NON-GAAP OPERATING RESULTS

(in thousands, except per share data)

(Unaudited)

Nine Months Ended September 30, 2007

Stock-based Write-off of Non-

GAAP compensation deferred debt GAAP

results expense issuance costs results

Revenues $90,605 $- $- $90,605

Cost of revenues 35,466 (434) - 35,032

Gross profit 55,139 434 - 55,573

Operating expenses:

Selling, general

and administrative 44,271 (3,486) - 40,785

Research and

development 15,241 (783) - 14,458

Amortization of

intangibles 2,313 - - 2,313

Total operating


'/>"/>

SOURCE Volcano Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Volcano Corporation Announces Proposed Public Offering of Common Stock
2. Volcano Corporation Reports Preliminary Third Quarter 2007 Revenues
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2008)...ewswire/ -- The HealthCentral,Network, Inc. (http...pConnection.com, a new online medical and peer-to-...hose struggling with obesity about,drugs, surgerie...scuss and,post questions., Three expert writers, .... Jeffrey Heit, television health reporter Amy Hen...
(Date:7/9/2008)...n that would cut $39 million from,Medicare Advanta...Newswire-USNewswire/ -- Seniors across,Mississippi...icare,Advantage program in legislation being consi...31) would cut $39 million from the Medicare Advant...back the areas where Medicare,private fee-for-serv...
(Date:7/9/2008)...n that would cut $38 million from,Medicare Advanta...ewswire-USNewswire/ -- Seniors across New Mexico,a...are Advantage program in,legislation being conside...) would cut $38 million from the Medicare Advantag...k the areas where Medicare private,fee-for-service...
(Date:7/9/2008)...a larger role in kidney transplants than previousl... well in men due to their smaller size. Women hav...Therefore, in the future, gender should be conside...esearchers from Basel and Heidelberg. , These re...ve Transplant Study", the world,s largest database...
Breaking Medicine News(10 mins):Health News:Responding to Increased Incidence of Obesity and Associated Health Issues, The HealthCentral Network Launches Site to Support those Struggling with Weight 2Health News:Mississippi Seniors Speak Out Against Medicare Advantage Cuts 2Health News:New Mexico Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Male kidneys for men only? 2
... offered an insight into the 'déjà vu' phenomenon,...ertain things before. // Leeds university research...ct in the memory process. Though all of us have ex...o-day life, for some people, this kind of a feelin...
...om Health Department as introduced new reforms to ...aims at giving better treatment at an affordable /... effective plan is aimed at concentration more at ... Secretary Patricia Hewitt on the new reforms as s...
...nister has promised his countrymen safe drinking w...reforms in governance are being given priority // ... India do not have access to safe drinking water. ...ters in charge of rural drinking water supply and ...
... mostly develops during young adulthood and scient...mood-altering drugs helps them to relieve of their... helps them to overcome the Manic depressive illne...lleagues from Yale’s Mood Disorder Research Progra...
Other Medicine News:Health News:Mystery Behind The Déjà Vu Phenomenon Yet To Be Resolv 2Health News:Safe Drinking Water To Be Made Available 2
(Date:7/8/2008)...K, July 8 /- McGraw-Hill Professional...es for the scientific and medical,communities, tod...ectiveness reference to its comprehensive online p...//www.accesspharmacy.com ). Through an alliance wi...ases generated from clinical,studies, AccessPharma...
(Date:7/7/2008)...HCV Development Presence Includes ANA598 and ANA77...Complementary Mechanisms Conferen...- Anadys Pharmaceuticals,I...suming clinical,investigation of the Toll-Like Rec...nic hepatitis C. Based on preclinical pharmacology...
(Date:7/7/2008)...NG, July 7 /- OrbusNeich today announ...l Meeting of the Japanese Society of,Interventiona...eered R,stent has better outcomes when compared to...ione, M.D., the study,s principal,investigator and...ples,s,Division of Cardiology, Department of Clini...
(Date:7/6/2008)...e basis for CTI,s Marketing Authorization Applicat...by the EMEA, SEATTLE, July 7 /PRNewswire-FirstCal... ; MTA) today announced the publication of results...XIO(TM) (paclitaxel poliglumex,CT-2103) with gemc...performance status 2) patients with previously unt...
Breaking Medicine Technology:McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 1Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 2Cardinal Health Completes Enturia Acquisition 2043 1Cardinal Health Completes Enturia Acquisition 2043 2Federal government taps NC State experts to explain nanotech risks 5330 1Federal government taps NC State experts to explain nanotech risks 5330 2Westaim announces 2008 first quarter results 19126 1Westaim announces 2008 first quarter results 19126 2Westaim announces 2008 first quarter results 19126 3
... 2007 /PRNewswire/ -- Prolexys,Pharmaceuticals and...erties of the selective small molecule anti-tumor ...company,s,chemi-proteomics technology to understan... to be published in the June 14, 2007 issue,of the...hondrial,voltage- dependent anion channels (VDACs)...
...07 /PRNewswire/ -- Two studies presented,today dem... peak,plasma levels, nor did it impair middle-of-t...n patients who suffer from chronic,insomnia. The r...nnual Meeting of the Associated Professional Sleep...ause they show that ROZEREM may be,a safe sleep me...
Other Medicine Technology:Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 2Prolexys Pharmaceuticals and Columbia University Researchers,Publish Study on Anti-Tumor Properties of a Selective Small,Molecule Anti-Tumor Agent With Novel Mechanism of Action 3Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 2Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 3Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 4Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 5
The Snellen chart remains to most popular chart design among clinicians. A range of different optotypes can be displayed in snellen format including British, sheridan-gardner, landolt Cs, tumbling Es
The PacScan 300AP is a portable, combination A-scan and pachymeter which provides easy-to-use touch screen operation. The combination of a high frequency, low noise probes and fast precise algorithms
Lightweight portable pachymeter, with compact LCD screen and optional printer. The Micropach 200P+ is extremely portable, weighing slightly more than 2 lbs (1 kg). The digital pachymeter provides a
16 segment Horizontal Prism bar provides 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 45 PD. 4446 xx Horizontal Prism Bar.
Medicine Products: